Role of podoplanin expression in esophageal squamous cell carcinoma: A retrospective study
Role of podoplanin expression in esophageal squamous cell carcinoma: A retrospective study
复制标题
DOI：
10.1111/j.1442-2050.2011.01211.x
复制
发表时间：
2012-01-01
影响因子：
2.6
通讯作者：
Zhang, H.
中科院分区：
文献类型：
--
作者：
Tong, L.;Yuan, S.;Zhang, H.
淋巴结转移是食管鳞状细胞癌（ESCC）患者生存率低的主要原因，因为没有可靠的方法预测早期转移。最近的研究表明podoplanin表达对淋巴结转移扩散的影响。本研究旨在探讨podoplanin表达对食管鳞癌淋巴结转移和肿瘤细胞的影响，以及podoplanin表达与食管鳞癌患者预后的关系。采用免疫组化D2-40法检测肿瘤细胞Podoplanin的表达水平及肿瘤组织与正常组织淋巴管密度的变化，并分析这两个变量与各种临床病理参数之间的相关性。podoplanin的表达与淋巴结转移的频率相关。在45例患者（80%）中，podoplanin在肿瘤细胞上表达。21例患者（37.5%）显示高水平表达。podoplanin高表达患者的5年无病生存率（5%）显著低于podoplanin低表达和中度表达患者（分别为54%和27%）（P < 0.001）。我们的结论是podoplanin在ESCC中频繁表达，并且podoplanin在癌细胞、淋巴管或两者上的表达与淋巴转移和临床结果相关。
Lymphatic metastasis is the predominant cause of the low overall survival of patients with esophageal squamous cell carcinoma (ESCC), as there are no faithful methods available predicting early metastasis. Recent studies suggest an effect of podoplanin expression on metastatic spreading to lymph nodes. The purpose of this study was to investigate the influence of podoplanin expression on lymphatic metastasis and tumor cells, and to find the relationship between podoplanin expression and prognosis of patients with ESCC. We evaluated the level of podoplanin expression on tumor cells and the lymphatic vessel density change of tumor mass compared with normal tissue from the same patient through D2-40 immunohistochemistry staining, and analyzed associations between these two variables and various clinicopathologic parameters individually or conjunctively. There was an association between podoplanin expression and the frequency of lymph node metastases. In 45 patients (80%), podoplanin was expressed on the tumor cells. Twenty-one patients (37.5%) showed high levels of expression. The 5-year disease-free survival rate (5%) for patients with high levels of podoplanin expression was significantly lower (P < 0.001) than for patients with low and moderate expression of podoplanin (54% and 27%, respectively). We concluded that podoplanin is expressed frequently in ESCC, and that the expression of podoplanin on cancer cells, lymphatics, or both is correlated with lymphatic metastasis and clinical outcome.